Global Consortium Inc (OTC:GCGX) Announced a number of material events today, starting with the Annual Report, and Quarterly report showing over $1.5 million in revenues. This is the first time the company has reported revenues in the seven figures, and it appears the LOI is pinned for a significant increase over these first revenues numbers. However, most notably was the sale of processing equipment, mimicking some of the larger Cannabis companies in the USA.
To break it down, it appears GCGX got all of its money back it paid for the equipment, plus the tenant improvements and all the money it spent getting the lease. This left the company in a very healthy financial position, which allowed it to divert a significant portion of dollars to increasing the brand, Indulge.
According to the filings today, the equipment was on the books for $800,000, while the brand it owns is valued at roughly $27 million dollars. This is a no-brainer for any cannabis producing company, as it essentially retained the money it spent for the equipment, which is now in full operation. As such, Indulge oils is what makes the company the income. The equipment (owned by the manufacturer entity) is just what processes the oil, which is then sold for profit for the company Indulge oils.
To add, their manufacturer is able to operate during the economic lock-down, which makes them one of the very few companies in the state who are permitted to produce during a state-wide lock down.
Our Manufacture is able to operate in CA since they hold a license for both Medical and Recreational. With the lockdown in place for all of CA, Medical Cannabis has been deemed an essential business for the patients of CA who need their medicine. Therefore, our Manufacturer is deemed an essential business and able to fully operate during state wide lockdowns.
Further, the company announced today that there will be no change in the share structure to allow for convertible debt. The is essential as it signals a major shift in the corporate mindset going into expansion territory. This is further personified by the announcement the company will be initiating a share buy back, with almost 20% in revenues being used for month buy backs. This will have a dramatic effect on the price of the stock, which makes sense as they plan to Uplist to OTCQB, which needs a consistent share price of $0.01 per share. Essentially, each month there will be a large number of shares being bought in the open market, while simultaneously lowering the share structure.
This new bonus for GCGX is signaling to some investors in the BRT space that the high revenues GCGX is producing is now in-line with “Penny Stock Exempt” status by OTCmarkets, possibly within 2020. “Penny Stock Exempt,” meaning that shares of the issuer is no longer a “Penny Stock” as defined in Rule 3a51-1, promulgated under the Securities Exchange Act of 1934, as amended.
To qualify as “Penny Stock Exempt” on the OTC Markets, an issuer must satisfy one of the following requirements: (i) the issuer’s securities have a minimum price greater than $5 per share; (ii) the issuer has average revenues of at least $6 million for the last three (3) years; or (iii) the issuer has net tangible assets exceeding $2 million, if the issuer has been in continuous operations for at least three (3) years or $5 million if less than three (3) years.
Taken together, it will be a very interesting year for GCGX, as well as all Cannabis companies in the remaining quarters of 2020. The company has further hinted at a S1 registration statement possibly in the summer, which would be a monumental shift for the company, allowing it to uplist to OTCQB and OTCQX. Time will tell, as investors continue to navigate through the choppy waters of the global markets.
Annual Report: HERE
First Quarter Report: HERE